A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-09-12. Anything still debated is marked as such rather than presented as settled.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
=== Deficiency === In humans methionine is an essential amino acid; cysteine is conditionally essential and may be synthesized from non-essential serine via sulfur salvaged from methionine. Sulfur deficiency is uncommon due to the ubiquity of cysteine and methionine in food. Isolated sulfite oxidase deficiency is a rare, fatal genetic disease caused by mutations to sulfite oxidase, which is needed to metabolize sulfites to sulfates.
Among unconfirmed and often contradictory news reports aired throughout the day, one of the most prevalent claimed a car bomb had been detonated at the U.S. State Department's headquarters in Washington, D.C., but the report was retracted. Another jet (Delta Air Lines Flight 1989) was suspected of having been hijacked, but the aircraft responded to controllers and landed safely in Cleveland, Ohio. Korean Air flight 085 diverted to Whitehorse, Yukon, Canada, surrounded by police snipers and Whitehorse airport and downtown evacuated after it responded to air traffic control to transmit a hijacking code but air traffic control interpreted it to mean an actual hijack and not merely a response to air traffic request. Prime Minister Jean Chretien of Canada had given the authorization to shoot down the Korean Air Boeing 747 if necessary. A single exception to the FAA's grounding order came on September 12, when a flight was authorized from Fort Lauderdale, to San Diego, and on to Miami to retrieve a rare antivenom for a professional snake handler who had been bitten by an inland taipan. In an April 2002 interview, Mohammed and bin al-Shibh, who are believed to have organized the attacks, said Flight 93's intended target was the United States Capitol, not the White House. During the planning stage of the attacks, Atta thought the White House might be too tough a target and sought an assessment from Hanjour.
== Honors and awards == 1971 ACS Award in Chemical Instrumentation 1981 ACS Award in Analytical Chemistry 1984 William H. Nichols Medal 1985 Oesper Award 1985 J. J. Thomson Gold Medal by International Mass Spectrometry Society 1987 Pittsburgh Analytical Chemistry Award 1989 Field and Franklin Award for Mass Spectrometry 1989 University of Naples Gold Medal 1992 Robert Boyle Gold Medal by the Royal Society of Chemistry 1996 Chemical Pioneer Award from the American Institute of Chemists 1997 Bijvoet Medal of the Bijvoet Center for Biomolecular Research. 1999 J. Heyrovsky Medal by the Czech Academy of Sciences 2000 G. Natta Gold Medal by Italian Chemical Society 2001 Torbern Bergman Medal by the Swedish Chemical Society 2003 John B. Fenn Distinguished Contribution in Mass Spectrometry by the American Society for Mass Spectrometry (ASMS) 2004 Lavoisier Medal by the French Chemical Society 2006 Pehr Edman Award by the International Association for Protein Structure 2015 Nakanishi Prize from the American Chemical Society 2019 American Chemical Society designated a National Historic Chemical Landmark in Midland, MI for the demonstration of the first operating GC-MS by Fred McLafferty and Roland Gohlke.
Sources: en.wikipedia.org
=== Synthesis of urea === Although not usually isolated as such, the salt ammonium carbamate is produced on a large scale as an intermediate in the production of the commodity chemical urea from ammonia and carbon dioxide.
After the Chong Bok border clash that led to a Cambodian soldier's death on 28 May 2025, Paetongtarn immediately directed the Ministry of Foreign Affairs to de-escalate tensions through official channels, while firmly affirming Thailand's territorial claims. She assured the public that her government had maintained continuous consultation with the armed forces following the border incident. She emphasized Thailand's commitment to peace while affirming the country's readiness to defend its citizens. In a public statement, she said, "Thailand is a peaceful nation, but we are fully prepared to protect our people. While we prioritise peaceful solutions, our military is ready should clashes occur." She gave a speech in parliament declaring: "We will not give away even one square inch of land, but we will not go to war over misunderstandings either." She also visited the tense border area to offer support but publicly insisted on a peaceful resolution, a position that stood in contrast to the tougher rhetoric from some military figures. Behind the scenes, Paetongtarn engaged in personal, informal diplomacy, leveraging the long-standing relationship between her family and former Cambodian Prime Minister Hun Sen. Her goal was to use this personal connection to defuse the situation. This led to a private phone call between the two leaders on 15 June 2025.
Abacavir (ABC), sold under the brand name Ziagen among others, is a medication used to treat HIV/AIDS. Similar to other nucleoside analog reverse-transcriptase inhibitors (NRTIs), abacavir is used together with other HIV medications, and is not recommended by itself. It is taken by mouth as a tablet or solution and may be used in children over the age of three months. Abacavir is generally well tolerated. Common side effects include vomiting, insomnia (trouble sleeping), fever, and feeling tired. Other common side effects include loss of appetite, headache, nausea (feeling sick), diarrhea, rash, and lethargy (lack of energy). More severe side effects include hypersensitivity, liver damage, and lactic acidosis. Genetic testing can indicate whether a person is at higher risk of developing hypersensitivity. Symptoms of hypersensitivity include rash, vomiting, and shortness of breath. Abacavir is in the NRTI class of medications, which work by blocking reverse transcriptase, an enzyme needed for HIV virus replication. Within the NRTI class, abacavir is a carbocyclic nucleoside. Abacavir was patented in 1988, and approved for use in the United States in 1998. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. Abacavir is used together with other HIV medications, such as abacavir/lamivudine/zidovudine, abacavir/dolutegravir/lamivudine, and abacavir/lamivudine. The combination abacavir/lamivudine is an essential medicine.
=== Anti-competitive practices === In February 2017, the European Commission began investigating Valve and five other publishers—Bandai Namco Entertainment, Capcom, Focus Home Interactive, Koch Media and ZeniMax Media—for anti-competitive practices, specifically the use of geo-blocking through the Steam storefront and Steam product keys to prevent access to software to citizens of certain countries. Such practices would be against the Digital Single Market initiative by the European Union. While the other five companies named are in stages of settling with the EU as of August 2019, Valve has stated it plans to fight the charges, asserting that geo-blocking affects less than 3% of its games, and that it had turned off such geo-blocking within the EU in 2015. In January 2021, five gamers filed a proposed class-action antitrust lawsuit in California against Valve, alleging that the company "abuses the Steam platform's market power" by requiring game developers and publishers to enter into a "most favored nation" agreement with Valve, restricting their ability to sell games for less on other platforms and thereby preventing price competition. This suit was later consolidated with the Wolfire Games lawsuit.
Sources: en.wikipedia.org
=== U.S. response on humanitarian aid === In May 2026, U.S. Secretary of State Marco Rubio said the United States had offered $100 million in humanitarian aid to Cuba, including food and medical supplies. He criticized the Cuban government, saying it was preventing humanitarian aid from reaching the population. The statement was made in the context of long-standing U.S. sanctions and trade restrictions on Cuba, which have restricted economic and humanitarian flows to the country. Rubio also described the situation in Cuba as "unacceptable" and called for major changes in the country's governance.
(1999), "Conditioned Arising Evolves: Variation and Change in Textual Accounts of the Paticca-samupadda Doctrine", Journal of the International Association of Buddhist Studies, 22 (2) Jurewicz, Joanna (2000), "Playing with Fire: The pratityasamutpada from the perspective of Vedic thought", Journal of the Pali Text Society, 26: 77–103 Shulman, Eviatar (2008), "Early Meanings of Dependent-Origination" (PDF), Journal of Indian Philosophy, 36 (2): 297–317, doi:10.1007/s10781-007-9030-8, S2CID 59132368, archived from the original (PDF) on 10 October 2016 Gombrich, Richard (2009), "Chaper 9. Causation and non-random process", What the Buddha Thought, Equinox Jones, Dhivan Thomas (2009), "New Light on the Twelve Nidanas", Contemporary Buddhism, 10 (2): 241–259, doi:10.1080/14639940903239793, S2CID 145413087
=== Mechanism of action === Opicapone blocks the enzyme catechol-O-methyltransferase (COMT) effectively (>90% at therapeutic doses), selectively and reversibly, and only outside the central nervous system. It dissociates slowly from COMT, resulting in a duration of action longer than 24 hours despite its short blood plasma half-life. As COMT and DOPA decarboxylase are the main enzymes for degrading levodopa, blocking the two effectively increases its concentrations in the bloodstream. More levodopa reaches the brain, where it is activated to dopamine.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.